Sinopharm to Acquire Lixin Pharmaceutical for RMB 3.5 Billion, Boosting Appetite for Innovation in Pharmaceutical Sector

4 week ago / Read about 0 minute

Author：小编

Sinopharm will acquire the remaining 95.09% stake in Lixin Pharmaceutical for approximately US$500 million, thereby making Lixin Pharmaceutical its wholly-owned subsidiary. Lixin Pharmaceutical boasts multiple promising FIC/BIC innovative drug pipelines and has secured licensing agreements totaling nearly US$4 billion with AstraZeneca and Merck Sharp & Dohme. This acquisition will allow Sinopharm to swiftly secure innovative assets, reducing R&D timeframes and costs. Industry analysts anticipate that this transaction will accelerate the trend of mergers and acquisitions within the pharmaceutical industry, intensify the focus on the 'innovative drugs + mergers and acquisitions' theme, and elevate the valuations of associated companies.

Previous page：TsingSan Bio Secures Tens of Millions in Pre-A+ Ro...

Next page：JD.com: Over 1,000 Families Team Up as 'Delivery S...

Return to List

Hot Reading

1 day ago

Cohere hires long-time Meta research head Joelle Pineau as its chief AI officer

2 day ago

Mark Zuckerberg claims to have an AI which is making itself smarter, and I'm scared

2 day ago

Google Gemini will now learn from your chats—unless you tell it not to

1 day ago

Upcoming DeepSeek AI model failed to train using Huawei’s chips